Association of prostate specific antigen (PSA) doubling time (DT) and prostate specific membrane antigen (PSMA) findings in biochemically recurrent prostate cancer (BCR).Melissa L. Abel, Ravi A. Madan, Esther Mena et al.|Journal of Clinical Oncology|2026Cited by 0
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.Ravi A. Madan, Melissa L. Abel, Katherine Lee-Wisdom et al.|Journal of Clinical Oncology|2026Cited by 0
Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.A. B. Warner, Ravi A. Madan, Melissa L. Abel et al.|Journal of Clinical Oncology|2026Cited by 0
Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.Melissa L. Abel, Ravi A. Madan, Fatima Karzai et al.|Journal of Clinical Oncology|2026Cited by 0
Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.Ravi A. Madan, Melissa L. Abel, Esther Mena et al.|Journal of Clinical Oncology|2026Cited by 0